Eli Lilly partners with Hims & Hers to expand access to Zepbound and Foundayo obesity medicines
Lilly's commercial partnership with Hims & Hers brings two FDA-approved obesity treatments into an integrated telehealth prescribing and delivery pathway, with published self-pay starting prices from $149 per month.
Eli Lilly and Hims & Hers announced a commercial access agreement on 6 November 2026 enabling eligible patients, following independent assessment and prescribing by licensed healthcare providers, to obtain Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers telehealth platform.
The arrangement combines virtual consultations, prescribing and home delivery, with published self-pay starting prices of $299 per month for Zepbound and $149 for Foundayo, while undisclosed commercial terms and the absence of any new regulatory approval distinguish the agreement from a drug-development licensing transaction.
Field | Content |
Article Type | Deals |
Company | Eli Lilly and Company |
Commercial Partner | Hims & Hers Health |
Deal Type | Commercial access and distribution partnership |
Announcement Date | 6 November 2026 |
Agreement Status | Announced |
Therapeutic Area | Obesity and weight management |
Product One | Zepbound |
Product One Active Ingredient | Tirzepatide |
Product Two | Foundayo |
Product Two Active Ingredient | Orforglipron |
Product Regulatory Status | FDA-approved medicines as described in the announcement |
Distribution Channel | Hims & Hers telehealth platform |
Patient Access Model | Virtual clinical assessment, prescribing and home delivery |
Prescribing Responsibility | Licensed healthcare providers |
Clinical Independence | Prescribing decisions remain with healthcare providers |
Eligible Population | Patients assessed as clinically eligible for the relevant treatment |
Zepbound Published Starting Price | $299 per month |
Foundayo Published Starting Price | $149 per month |
Pricing Basis | Published self-pay starting prices |
Geographic Market | United States |
Commercial Consideration | Not disclosed |
Upfront Payment | Not disclosed |
Milestone Payments | Not disclosed |
Acquisition Involved | No |
New FDA Approval Announced | No |
What Happened | Eli Lilly and Hims & Hers agreed to expand access to two Lilly obesity medicines through a telehealth distribution arrangement. |
Why It Matters | The partnership creates an additional patient access channel for branded obesity treatments through integrated virtual healthcare services. |
Strategic Significance | Extends Lilly's commercial reach through an established direct-to-consumer telehealth platform. |
Financial Clarification | Published patient self-pay prices are not financial consideration paid between the companies. |
Key Takeaway | The agreement expands commercial access to Zepbound and Foundayo without transferring drug-development rights or announcing a new regulatory approval. |
What to Watch | Patient uptake, treatment affordability, prescribing access, distribution implementation and any subsequent commercial disclosures. |
Primary Source | Eli Lilly and Company |
Primary Source URL | https://investor.lilly.com/news-releases/news-release-details/lilly-and-hims-hers-expand-access-fda-approved-lilly-medicines |
Relevant Date | 6 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios